ArticleBreast cancer research and treatment2012
Willingness to use tamoxifen to prevent breast cancer among diverse women.
Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia.The oncologist · 2022Trial
- Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial.Breast (Edinburgh, Scotland) · 2015Trial
- A randomized, controlled trial to increase discussion of breast cancer in primary care.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Trial
- Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection.Frontiers in pharmacology · 2026Review
- The symptom burden of women with a known risk of breast cancer receiving risk reducing medication.Cancer treatment and research communications · 2025Article
- Comparing Breast Cancer and Cardiovascular Disease Risk and Use of Chemoprevention and Statins among Women with High-risk Breast Lesions.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Socio-culturally mediated factors and lower level of education are the main influencers of functional cervical cancer literacy among women in Mayuge, Eastern Uganda.Ecancermedicalscience · 2020Article
- Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Article
- Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal CarcinomaCancer prevention research (Philadelphia, Pa.) · 2017Article
- Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.PloS one · 2017Article
- Letter to the Editor: Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use: Scientific Views.Journal of Korean medical science · 2016Article
- Article
- Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.Breast (Edinburgh, Scotland) · 2015Article
- Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.Ecancermedicalscience · 2015Review
- Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.British journal of cancer · 2014Article
- Tamoxifen for women at high risk of breast cancer.Breast cancer (Dove Medical Press) · 2014Review
- Colorectal cancer screening: what do women from diverse ethnic groups want?Journal of general internal medicine · 2013Article
- Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.Breast cancer research and treatment · 2012Article
- Factors Associated with Women's Unwillingness to Decrease Alcohol Intake to Decrease Breast Cancer Risk.Journal of primary care & community healthArticle
- Physician and Patient Barriers to Breast Cancer Preventive Therapy.Current breast cancer reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
Use of chemoprevention to prevent development of breast cancer among high-risk women has been limited despite clinical evidence of its benefit. Our goals were to determine whether knowledge of the benefits and risks of tamoxifen affects a woman's willingness to take it to prevent breast cancer, to define factors associated with willingness to take tamoxifen, and to evaluate race/ethnic differences. Women, ages 50-80, who identified as African American, Asian, Latina, or White, and who had at least one visit to a primary care physician in the previous 2 years, were recruited from ambulatory practices. After a screening telephone survey, women completed an in-person interview in their preferred language. Multivariate regression models were constructed to examine the associations of demographic characteristics, numeracy, breast cancer history, and health knowledge with willingness to take tamoxifen. Over 40% of the women reported they would likely take tamoxifen if determined to be at high risk, and 31% would be somewhat likely to do so. Asian women, those with no insurance, and those with less than high school education were significantly more likely to be willing to take tamoxifen. Higher scores on numeracy and on breast cancer knowledge were also associated with willingness to take tamoxifen. A higher tamoxifen knowledge score was inversely related to willingness to take the drug. Factors affecting women's willingness to take breast cancer chemoprevention drugs vary and are not determined solely by knowledge of risk/benefit or risk perception.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.